Amundi Sells 7,291,854 Shares of Pfizer Inc. $PFE

Key Points

• Amundi reduced its Pfizer stake by 17.9% in the second quarter, selling 7.29 million shares and retaining 33.53 million shares valued at approximately $807.5 million.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, beating analyst estimates, while maintaining 2026 EPS guidance of $2.80–$3.00. The company also pays a $0.43 quarterly dividend, representing a 6.1% yield.
• Pfizer’s pipeline and recent developments include FDA approval for an updated COVID-19 vaccine, a Phase 3 obesity-drug trial, and a licensing deal worth up to $1 billion; however, analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Amundi trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 17.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,533,616 shares of the biopharmaceutical company's stock after selling 7,291,854 shares during the period. Amundi owned 0.59% of Pfizer worth $807,488,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter worth $26,000. Field & Main Bank purchased a new stake in shares of Pfizer in the second quarter worth $27,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the period. 68.36% of the stock is owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups. The approval supports continued vaccine revenue and adds to the company’s recent positive news flow. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer launched the VESPER-JM Phase 3 study of berobenatide in Japan, strengthening its effort to compete in the obesity-drug market. Successful development could provide a meaningful long-term growth opportunity beginning later this decade. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
• Positive Sentiment: Pfizer’s broader pipeline remains focused on obesity and oncology, with berobenatide and next-generation cancer treatments viewed as potential growth drivers from 2028 onward. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
• Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal valued at up to $1 billion plus royalties. The agreement could generate milestone and royalty income while sharing development responsibilities. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Neutral Sentiment: Pfizer completed a Phase 1 migraine-tablet study and is conducting a Phase 3 trial of tilrekimig for eczema. These updates demonstrate pipeline activity, but they do not yet provide confirmed commercial revenue. Pfizer’s Tilrekimig Eczema Trial
• Negative Sentiment: After gaining roughly 25% over the past year and trading near recent highs, valuation-based upside appears more limited. Investors are also weighing Pfizer’s elevated dividend yield and management’s commitment to maintaining the payout against ongoing post-pandemic earnings pressure.

Pfizer Price Performance

NYSE:PFE opened at $28.42 on Monday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $161.98 billion, a P/E ratio of 37.40, a P/E/G ratio of 1.91 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The business's 50-day moving average is $25.98 and its 200 day moving average is $26.34.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company posted $0.78 EPS. The company's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a $0.43 dividend. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's payout ratio is 226.32%.

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. Wolfe Research reaffirmed an "underperform" rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. Cantor Fitzgerald restated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. JPMorgan Chase & Co. dropped their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Finally, HSBC downgraded Pfizer from a "buy" rating to a "hold" rating and decreased their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source